Clarity Pharmaceuticals Ltd (FRA:1F4)

Market Cap	367.89M -63.2%
Revenue (ttm)	6.37M +11.2%
Net Income	-64.94M
EPS	-0.18
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	342
Open	0.9600
Previous Close	1.0200
Day's Range	0.9600 - 0.9600
52-Week Range	0.9600 - 2.5690
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 100
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1F4

Financial Performance

In fiscal year 2026, Clarity Pharmaceuticals's revenue was 10.53 million, an increase of 11.24% compared to the previous year's 9.46 million. Losses were -107.24 million, 66.8% more than in 2025.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error